The antibiotic drug tigecycline: A focus on its promising anticancer properties
Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00473/full |
| _version_ | 1818498272543637504 |
|---|---|
| author | Zhijie Xu Zhijie Xu Yuanliang Yan Zhi Li Long Qian Zhicheng Gong |
| author_facet | Zhijie Xu Zhijie Xu Yuanliang Yan Zhi Li Long Qian Zhicheng Gong |
| author_sort | Zhijie Xu |
| collection | DOAJ |
| description | Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, future clinical trials are discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG. |
| first_indexed | 2024-12-10T18:56:03Z |
| format | Article |
| id | doaj.art-563ce1fd94b3477e9bf6e85a183598a4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-10T18:56:03Z |
| publishDate | 2016-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-563ce1fd94b3477e9bf6e85a183598a42022-12-22T01:37:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-12-01710.3389/fphar.2016.00473227558The antibiotic drug tigecycline: A focus on its promising anticancer propertiesZhijie Xu0Zhijie Xu1Yuanliang Yan2Zhi Li3Long Qian4Zhicheng Gong5Department of Pathology, Xiangya Hospital, Central South UniversityDepartment of Pathology, School of Basic Medicine, Central South UniversityDepartment of Pharmacy, Institute of Hospital Pharmacy, Xiangya Hospital, Central South UniversityCenter for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South UniversityDepartment of Pharmacy, Institute of Hospital Pharmacy, Xiangya Hospital, Central South UniversityDepartment of Pharmacy, Institute of Hospital Pharmacy, Xiangya Hospital, Central South UniversityTigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, future clinical trials are discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00473/fullclinical trialsMitochondrial functiontigecyclineAKT signalingAnti-cancer effects |
| spellingShingle | Zhijie Xu Zhijie Xu Yuanliang Yan Zhi Li Long Qian Zhicheng Gong The antibiotic drug tigecycline: A focus on its promising anticancer properties Frontiers in Pharmacology clinical trials Mitochondrial function tigecycline AKT signaling Anti-cancer effects |
| title | The antibiotic drug tigecycline: A focus on its promising anticancer properties |
| title_full | The antibiotic drug tigecycline: A focus on its promising anticancer properties |
| title_fullStr | The antibiotic drug tigecycline: A focus on its promising anticancer properties |
| title_full_unstemmed | The antibiotic drug tigecycline: A focus on its promising anticancer properties |
| title_short | The antibiotic drug tigecycline: A focus on its promising anticancer properties |
| title_sort | antibiotic drug tigecycline a focus on its promising anticancer properties |
| topic | clinical trials Mitochondrial function tigecycline AKT signaling Anti-cancer effects |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00473/full |
| work_keys_str_mv | AT zhijiexu theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhijiexu theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT yuanliangyan theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhili theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT longqian theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhichenggong theantibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhijiexu antibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhijiexu antibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT yuanliangyan antibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhili antibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT longqian antibioticdrugtigecyclineafocusonitspromisinganticancerproperties AT zhichenggong antibioticdrugtigecyclineafocusonitspromisinganticancerproperties |